Filing Details

Accession Number:
0001209191-18-062480
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2018-12-13 17:04:16
Reporting Period:
2018-12-07
Accepted Time:
2018-12-13 17:04:16
Original Submission Date:
2018-12-11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1169245 Phasebio Pharmaceuticals Inc PHAS Pharmaceutical Preparations (2834) 030375697
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1313942 P Jonathan Mow C/O Phasebio Pharmaceuticals, Inc.
1 Great Valley Parkway, Suite 30
Malvern PA 19355
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-12-07 700 $3.89 49,399 No 4 P Indirect By the Mow Trust dated April 17, 2008
Common Stock Acquisiton 2018-12-10 800 $3.85 50,199 No 4 P Indirect By the Mow Trust dated April 17, 2008
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By the Mow Trust dated April 17, 2008
No 4 P Indirect By the Mow Trust dated April 17, 2008
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.73 to $4.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
  2. The reporting person and his wife are joint trustees of the Mow Trust dated April 17, 2008 and share voting and dispositive power for such shares. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
  3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.80 to $3.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.